Amgen (AMGN) stock is in focus as partner Kissei (KSPHF) reports 20 deaths linked to the U.S. company's rare disease drug.

May 15 (Reuters) - About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with ...

Twenty people in Japan died after taking Tavneos, though it's unclear whether the drug killed those people, a media report ...

The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely ...

About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with Amgen's rare disease ...

If you are wondering whether Amgen’s current share price reflects its true worth, starting with a clear look at what the ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...

Investors in Amgen Inc. AMGN need to pay close attention to the stock based on moves in the options market lately. That is ...

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. | A quantum ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...